HOTH - Hoth extends Washington Uni. Alzheimer's mouse model study with its HT-ALZ therapeutic

Hoth Therapeutics (NASDAQ:HOTH) on Thursday said it had entered into an extension of its research agreement with the Washington University in St. Louis, Mo. for the continued R&D of Hoth's HT-ALZ, a therapeutic for the treatment of Alzheimer's disease. HOTH stock -3.9% to $0.42 in premarket trading. It had ended 4.3% higher in the previous session. The goal of the additional studies would be to determine if HT-ALZ can improve learning and memory in a mouse model of Alzheimer's disease. The outcome of the additional studies would be to estimate a human equivalent dose of HT-ALZ for starting human clinical trials.

For further details see:

Hoth extends Washington Uni. Alzheimer's mouse model study with its HT-ALZ therapeutic